The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

(Reuters) -Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

London’s FTSE 100 was up 0.2% at 8,986.82 in afternoon trade on Friday. BP was in the black as the oil giant agreed to sell ...

Softcat PLC (LSE:SCT) shares fell 4.5% on Thursday after JPMorgan warned that earnings expectations may be too high, raising concerns about ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

FDA panel rejects GSK's Blenrep combo due to severe ocular toxicity and dosing concerns in multiple myeloma trials ahead of ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

An important point about the updated guidelines is the emphasis on individualized treatment of complicated UTIs, recognizing ...